Acetaminophen Butalbital

證據等級: L5

預測適應症: 0 個

Acetaminophen + Butalbital: Insufficient Data for Repurposing Evaluation

One-Sentence Summary

Acetaminophen + Butalbital is a combination analgesic-barbiturate product, classically used for tension-type headaches in markets where it is approved (e.g., the United States under brand names such as Fioricet/Fiorinal). The TxGNN model returned no predicted new indications for this combination, and the drug is not currently marketed in Taiwan, meaning no regulatory baseline exists for this jurisdiction. The overall evidence base for repurposing evaluation is insufficient at this time.

Quick Overview

Item	Content
Original Indication	Tension-type headache (based on global market knowledge; no Taiwan license found)
Predicted New Indication	None (TxGNN returned no candidates)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model returned no predictions
US Market Status	Not marketed in Taiwan (0 licenses on record)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Acetaminophen acts as a centrally and peripherally acting analgesic/antipyretic (inhibiting prostaglandin synthesis), while Butalbital is a short-acting barbiturate that produces CNS depression and muscle relaxation, contributing to headache relief through sedation and vascular smooth muscle relaxation.

The combination’s efficacy is well established in tension-type headaches and analgesic-associated headache syndromes in markets such as the United States, but it carries significant dependency and rebound headache risks due to the barbiturate component.

Because TxGNN returned zero repurposing candidates for this combination, no mechanistic bridge to a new indication can be constructed at this stage. Repurposing evaluation cannot proceed without at minimum one candidate indication for analysis.

Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication (TxGNN predicted no new indications).

Literature Evidence

Currently no related literature available for a repurposing indication (TxGNN predicted no new indications).

US Market Information

This drug combination has no registered licenses in Taiwan. No authorization table can be generated.

For reference: In the United States, Acetaminophen + Butalbital ± Caffeine products (e.g., Fioricet, Fiorinal) have been marketed for tension headache, but these approvals are not reflected in the Taiwan TFDA database for this query.

Safety Considerations

Please refer to the package insert for safety information.

Note: All safety fields (warnings, contraindications, drug interactions) returned data gaps in this Evidence Pack. Drug interaction data was also not found in the DDI query. Given that Butalbital is a barbiturate with known CNS depressant effects, clinicians should be aware of:

Potential for physical dependence and withdrawal

Additive CNS depression with alcohol, opioids, benzodiazepines

Hepatotoxicity risk from Acetaminophen in overdose or hepatic impairment

These are general pharmacological considerations, not derived from structured data in this pack.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN returned no repurposing candidates for this combination, and the drug has no Taiwan regulatory baseline, no MOA data, and no safety data in this Evidence Pack — making a formal repurposing evaluation impossible at this stage.

To proceed, the following is needed:

Resolve Data Gap DG001: Retrieve TFDA package insert PDF to extract warnings and contraindications (severity: Blocking)
Resolve Data Gap DG002: Query DrugBank API for MOA data (severity: High)
Re-run TxGNN on individual components (Acetaminophen alone, Butalbital alone) to determine whether the combination’s null result reflects a model limitation or a genuine absence of repurposing signal
Confirm jurisdictional scope: Determine whether US NDA data (Fioricet/Fiorinal) should be incorporated as a surrogate regulatory baseline
Assess individual component candidates: Acetaminophen has extensive repurposing literature (e.g., anti-inflammatory, antipyretic adjunct); evaluating components separately may yield actionable signals
Once candidate indications are identified, re-generate the Evidence Pack with populated predicted_indications to proceed to a full L1–L5 evidence review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.